{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T16:04:21Z","timestamp":1789315461220,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,13]]},"DOI":"10.7759\/cureus.116178","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T16:01:00Z","timestamp":1789315260000},"source":"Crossref","is-referenced-by-count":0,"title":["Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan"],"prefix":"10.7759","author":[{"given":"Robert B","family":"Raffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2002.4.4\/rnagata","article-title":"Japanese pharmaceutical and regulatory environment","volume":"4","author":"Nagata R","year":"2002","unstructured":"Nagata R, Rafizadeh-Kabe JD. Japanese pharmaceutical and regulatory environment. Dialogues Clin Neurosci. 2002, 4:470-474. 10.31887\/DCNS.2002.4.4\/rnagata","journal-title":"Dialogues Clin Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00071","article-title":"The promise of psychedelic science","volume":"4","author":"Olson DE","year":"2021","unstructured":"Olson DE. The promise of psychedelic science. ACS Pharmacol Transl Sci. 2021, 4:413-415. 10.1021\/acsptsci.1c00071","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref3","article-title":"Executive Order 14401: Accelerating medical treatments for serious mental illness","volume":"91","author":"Trump DJ","year":"2026","unstructured":"Trump DJ. Executive Order 14401: Accelerating medical treatments for serious mental illness. Federal Register. 2026, 91:21709-11.","journal-title":"Federal Register"},{"key":"ref4","unstructured":"FDA accelerates action on treatments for serious mental illness following executive order. (2026). Accessed. July 12, 2026: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-accelerates-action-treatments-serious-mental-illness-followin...."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9103509\/v1","article-title":"Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC [PREPRINT]","author":"Meinhardt M","year":"2026","unstructured":"Meinhardt M, Skorodumov I, Walter F, et al.. Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC [PREPRINT]. Res Sq. 2026, 10.21203\/rs.3.rs-9103509\/v1","journal-title":"Res Sq"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116337","article-title":"Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): a dose-response network meta-analysis of randomized placebo-controlled clinical trials","volume":"344","author":"Swieczkowski D","year":"2025","unstructured":"Swieczkowski D, Kwa\u015bny A, Pruc M, Gaca Z, Szarpak L, Cuba\u0142a WJ. Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): a dose-response network meta-analysis of randomized placebo-controlled clinical trials. Psychiatry Res. 2025, 344:116337. 10.1016\/j.psychres.2024.116337","journal-title":"Psychiatry Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00837","article-title":"FDA breakthrough therapy designation reduced late-stage drug development time","volume":"43","author":"Miller KL","year":"2024","unstructured":"Miller KL, Stern AD, Kearsley A, Kao J. FDA breakthrough therapy designation reduced late-stage drug development time. Health Aff (Millwood). 2024, 43:1003-1010. 10.1377\/hlthaff.2023.00837","journal-title":"Health Aff (Millwood)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/can.2025.0006","article-title":"How has Japan's Cannabis Control Act been amended?","volume":"11","author":"Masataka Y","year":"2026","unstructured":"Masataka Y, Akahoshi Y, Katayama M, et al.. How has Japan's Cannabis Control Act been amended?. Cannabis Cannabinoid Res. 2026, 11:284-292. 10.1089\/can.2025.0006","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-017-0126-5","article-title":"Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study","volume":"5","author":"Mahlich J","year":"2018","unstructured":"Mahlich J, Tsukazawa S, Wiegand F. Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study. Drugs Real World Outcomes. 2018, 5:35-43. 10.1007\/s40801-017-0126-5","journal-title":"Drugs Real World Outcomes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1549-7","article-title":"Key information providers, channels, and characteristics of Japanese consumers' informed choices of over-the-counter medications","volume":"4","author":"Hayashi M","year":"2015","unstructured":"Hayashi M, Masuda S, Kimura H. Key information providers, channels, and characteristics of Japanese consumers' informed choices of over-the-counter medications. Springerplus. 2015, 4:737. 10.1186\/s40064-015-1549-7","journal-title":"Springerplus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S98099","article-title":"Medicine reclassification processes and regulations for proper use of over-the-counter self-care medicines in Japan","volume":"9","author":"Nomura K","year":"2016","unstructured":"Nomura K, Kitagawa Y, Yuda Y, Takano-Ohmuro H. Medicine reclassification processes and regulations for proper use of over-the-counter self-care medicines in Japan. Risk Manag Healthc Policy. 2016, 9:173-183. 10.2147\/RMHP.S98099","journal-title":"Risk Manag Healthc Policy"},{"key":"ref12","unstructured":"Japanese Law Translation. Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices (Act no. 145 of 1960). (2015). Accessed. July 12, 2026: https:\/\/www.japaneselawtranslation.go.jp\/en\/laws\/view\/3213."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70022","article-title":"Expediting drug development in Japan: a PMDA perspective","volume":"118","author":"Kohno Y","year":"2025","unstructured":"Kohno Y, Ishiguro A, Yasukawa T, et al.. Expediting drug development in Japan: a PMDA perspective. Clin Pharmacol Ther. 2025, 118:1262-1264. 10.1002\/cpt.70022","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2080","article-title":"Evolving landscape of new drug approval in Japan and lags from international birth dates: retrospective regulatory analysis","volume":"109","author":"Tanaka M","year":"2021","unstructured":"Tanaka M, Idei M, Sakaguchi H, et al.. Evolving landscape of new drug approval in Japan and lags from international birth dates: retrospective regulatory analysis. Clin Pharmacol Ther. 2021, 109:1265-1273. 10.1002\/cpt.2080","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262550","article-title":"Lingering effects of COVID-19 on the mental health of first-year university students in Japan","volume":"17","author":"Horita R","year":"2022","unstructured":"Horita R, Nishio A, Yamamoto M. Lingering effects of COVID-19 on the mental health of first-year university students in Japan. PLoS One. 2022, 17:e0262550. 10.1371\/journal.pone.0262550","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796015000566","article-title":"Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey","volume":"25","author":"Ishikawa H","year":"2016","unstructured":"Ishikawa H, Kawakami N, Kessler RC. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey. Epidemiol Psychiatr Sci. 2016, 25:217-229. 10.1017\/S2045796015000566","journal-title":"Epidemiol Psychiatr Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin GM","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al.. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022, 387:1637-1648. 10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251368360","article-title":"Concomitant use of antidepressants and classic psychedelics: a scoping review","volume":"39","author":"Tap SC","year":"2025","unstructured":"Tap SC, Thomas K, P\u00e1len\u00ed\u010dek T, Stenb\u00e6k DS, Oliveira-Maia AJ, van Dalfsen JH, Schoevers RA. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol. 2025, 39:1072-1088. 10.1177\/02698811251368360","journal-title":"J Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05876-x","article-title":"Serotonin toxicity of serotonergic psychedelics","volume":"239","author":"Malcolm B","year":"2022","unstructured":"Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics. Psychopharmacology (Berl). 2022, 239:1881-1891. 10.1007\/s00213-021-05876-x","journal-title":"Psychopharmacology (Berl)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2165\/11317010-000000000-00000","article-title":"Interactions between herbal medicines and prescribed drugs: an updated systematic review","volume":"69","author":"Izzo AA","year":"2009","unstructured":"Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009, 69:1777-1798. 10.2165\/11317010-000000000-00000","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241237873","article-title":"The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients","volume":"38","author":"Knuijver T","year":"2024","unstructured":"Knuijver T, Ter Heine R, Schellekens AF, et al.. The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients. J Psychopharmacol. 2024, 38:481-488. 10.1177\/02698811241237873","journal-title":"J Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283505d5e","article-title":"PharmGKB summary: caffeine pathway","volume":"22","author":"Thorn CF","year":"2012","unstructured":"Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB. PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012, 22:389-395. 10.1097\/FPC.0b013e3283505d5e","journal-title":"Pharmacogenet Genomics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00294","article-title":"DARK classics in chemical neuroscience: ibogaine","volume":"9","author":"Wasko MJ","year":"2018","unstructured":"Wasko MJ, Witt-Enderby PA, Surratt CK. DARK classics in chemical neuroscience: ibogaine. ACS Chem Neurosci. 2018, 9:2475-2483. 10.1021\/acschemneuro.8b00294","journal-title":"ACS Chem Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2024-0110","article-title":"Challenges in regulating synthetic new psychoactive substances: lessons from Japan's generic scheduling against hexahydrocannabihexol","volume":"8","author":"Yokoyama N","year":"2025","unstructured":"Yokoyama N, Ikejiri T, Hakariya H. Challenges in regulating synthetic new psychoactive substances: lessons from Japan's generic scheduling against hexahydrocannabihexol. JMA J. 2025, 8:270-272. 10.31662\/jmaj.2024-0110","journal-title":"JMA J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283629ce9","article-title":"Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes","volume":"23","author":"Fohner A","year":"2013","unstructured":"Fohner A, Muzquiz LI, Austin MA, et al.. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics. 2013, 23:403-414. 10.1097\/FPC.0b013e3283629ce9","journal-title":"Pharmacogenet Genomics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/molecules20022208","article-title":"The anti-addiction drug ibogaine and the heart: a delicate relation","volume":"20","author":"Koenig X","year":"2015","unstructured":"Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015, 20:2208-2228. 10.3390\/molecules20022208","journal-title":"Molecules"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.0665","article-title":"Toward risk-benefit assessments in psychedelic- and MDMA-assisted therapies","volume":"79","author":"Bradberry MM","year":"2022","unstructured":"Bradberry MM, Gukasyan N, Raison CL. Toward risk-benefit assessments in psychedelic- and MDMA-assisted therapies. JAMA Psychiatry. 2022, 79:525-527. 10.1001\/jamapsychiatry.2022.0665","journal-title":"JAMA Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/add.70307","article-title":"Addiction-related problems in Japan: a regional perspective","volume":"121","author":"Ide S","year":"2026","unstructured":"Ide S, Nishitani Y, Sumitani M, et al.. Addiction-related problems in Japan: a regional perspective. Addiction. 2026, 121:1316-1324. 10.1111\/add.70307","journal-title":"Addiction"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2020.09.035","article-title":"Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: a systematic review","volume":"119","author":"Ona G","year":"2020","unstructured":"Ona G, Bouso JC. Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: a systematic review. Neurosci Biobehav Rev. 2020, 119:194-203. 10.1016\/j.neubiorev.2020.09.035","journal-title":"Neurosci Biobehav Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241278769","article-title":"Less is more? A review of psilocybin microdosing","volume":"38","author":"Savides IA","year":"2024","unstructured":"Savides IA, Outhoff K. Less is more? A review of psilocybin microdosing. J Psychopharmacol. 2024, 38:846-860. 10.1177\/02698811241278769","journal-title":"J Psychopharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12140","article-title":"Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan","volume":"36","author":"Feng LY","year":"2020","unstructured":"Feng LY, Wada K, Chung H, Han E, Li JH. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan. Kaohsiung J Med Sci. 2020, 36:135-142. 10.1002\/kjm2.12140","journal-title":"Kaohsiung J Med Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.25-00163-3","article-title":"Providing Evidence to Support Pharmacists as Gatekeepers of Overdose Prevention [Article in Japanese]","volume":"146","author":"Nagashima K","year":"2026","unstructured":"Nagashima K, Sekine Y. Providing Evidence to Support Pharmacists as Gatekeepers of Overdose Prevention [Article in Japanese]. Yakugaku Zasshi. 2026, 146:315-318. 10.1248\/yakushi.25-00163-3","journal-title":"Yakugaku Zasshi"},{"key":"ref33","article-title":"Pharmaceutical education in Japan - past, present -, and human social pharmacy education in the near future","volume":"50","author":"Okuda J","year":"2015","unstructured":"Okuda J. Pharmaceutical education in Japan - past, present -, and human social pharmacy education in the near future. Jpn J History Pharm. 2015, 50:175-180.","journal-title":"Jpn J History Pharm"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.01.029","article-title":"Toxicological considerations of Kampo medicines in clinical use","volume":"198","author":"Ikegami F","year":"2004","unstructured":"Ikegami F, Fujii Y, Satoh T. Toxicological considerations of Kampo medicines in clinical use. Toxicology. 2004, 198:221-228. 10.1016\/j.tox.2004.01.029","journal-title":"Toxicology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjsrh-2024-202221","article-title":"Japan initiates a groundbreaking market test of over-the-counter emergency contraceptive pills with pharmacies as a first access point","volume":"50","author":"Hakariya H","year":"2024","unstructured":"Hakariya H, Hashimoto T, Suzuki Y, Hamaki T, Tanimoto T. Japan initiates a groundbreaking market test of over-the-counter emergency contraceptive pills with pharmacies as a first access point. BMJ Sex Reprod Health. 2024, 50:230-231. 10.1136\/bmjsrh-2024-202221","journal-title":"BMJ Sex Reprod Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526295-implications-of-potential-us-fda-approval-of-psychedelics-or-psychedelic-adjacents-such-as-ibogaine-for-pharmacy-in-japan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T16:01:02Z","timestamp":1789315262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526295-implications-of-potential-us-fda-approval-of-psychedelics-or-psychedelic-adjacents-such-as-ibogaine-for-pharmacy-in-japan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.116178","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,13]]}}}